Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar 24:5:121.
doi: 10.3389/fimmu.2014.00121. eCollection 2014.

Bacterial outer membrane vesicles and vaccine applications

Reinaldo Acevedo  1 , Sonsire Fernández  1 , Caridad Zayas  1 , Armando Acosta  1 , Maria Elena Sarmiento  1 , Valerie A Ferro  2 , Einar Rosenqvist  3 , Concepcion Campa  1 , Daniel Cardoso  1 , Luis Garcia  1 , Jose Luis Perez  1
Affiliations
Review

Bacterial outer membrane vesicles and vaccine applications

Reinaldo Acevedo et al. Front Immunol. .

Abstract

Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit remarkable potential for immunomodulation of immune responses and delivery of meningococcal antigens or unrelated antigens incorporated into the vesicle structure. This paper reviews different applications in OMV Research and Development (R&D) and provides examples of OMV developed and evaluated at the Finlay Institute in Cuba. A Good Manufacturing Practice (GMP) process was developed at the Finlay Institute to produce OMV from N. meningitidis serogroup B (dOMVB) using detergent extraction. Subsequently, OMV from N. meningitidis, serogroup A (dOMVA), serogroup W (dOMVW), and serogroup X (dOMVX) were obtained using this process. More recently, the extraction process has also been applied effectively for obtaining OMV on a research scale from Vibrio cholerae (dOMVC), Bordetella pertussis (dOMVBP), Mycobacterium smegmatis (dOMVSM), and BCG (dOMVBCG). The immunogenicity of the OMV has been evaluated for specific antibody induction, and together with functional bactericidal and challenge assays in mice has shown their protective potential. dOMVB has been evaluated with non-neisserial antigens, including with a herpes virus type 2 glycoprotein, ovalbumin, and allergens. In conclusion, OMV are proving to be more versatile than first conceived and remain an important technology for development of vaccine candidates.

Keywords: Bordetella pertussis; Mycobacterium tuberculosis; Neisseria meningitidis; Vibrio cholerae; adjuvant; outer membrane vesicles; proteoliposomes; vaccines.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the dOMV extraction process and two micrographs of OMV obtained using this technology with two different detergents: OMV from N. meningitidis serogroup B extracted with deoxycholate (10) and OMV from V. cholerae O1 extracted with sodium dodecyl sulfate (37). OMV have a similar size and vesicle like structure. Differences observed between micrographs are mainly due to changes in magnification and stains used.
See this image and copyright information in PMC

References

    1. Lowell GH, Ripley BW, Smith LF, Wirtz RA, Zollinger WD, Hockmeyer WT. Proteasome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science (1988) 240:800–210.1126/science.2452484 - DOI - PubMed
    1. Mesa C, de Leon J, Fernandez LE. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine (2006) 24(14):2692–910.1016/j.vaccine.2005.01.114 - DOI - PubMed
    1. Holst JD, Martin R, Campa C, Oster P, O’Hallahan J, Rosenqvist E. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine (2009) 30S:B10–710.1016/j.vaccine.2009.04.071 - DOI - PubMed
    1. Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine (2009) 27S:B71–710.1016/j.vaccine.2009.04.070 - DOI - PMC - PubMed
    1. Van der Ley P, van den Dobbelsteen G. Next generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum Vaccin (2011) 7(8):886–9010.4161/hv.7.8.16086 - DOI - PubMed